Navigation Links
Novel mutations define 2 types of bone tumor
Date:10/27/2013

Scientists have made a rare discovery that allows them to attribute two types of tumour almost entirely to specific mutations that lie in two related genes.

These mutations are found in nearly 100 per cent of patients suffering from two rare bone tumours; chondroblastoma and giant cell tumour of the bone.

Chondroblastoma and giant cell tumour of bone are benign bone tumours that primarily affect adolescents and young adults, respectively. They can be extremely debilitating tumours and recur despite surgery. Occasionally, these tumours can be difficult to differentiate from highly malignant bone cancers. The mutations found in this study may be used for diagnosis of chondroblastoma and giant cell tumour. In addition, the mutations offer a starting point into research for a specific treatment against these tumours.

"This is an exceptional, if not a once in a lifetime discovery for the team," says Dr Peter Campbell, co-lead author of the study from the Wellcome Trust Sanger Institute. "What we normally see is that the same mutations occur in many different types of tumour. These mutations, however, are highly specific to these tumours. Moreover, our findings suggest that these mutations are the key, if not the sole, driving force behind these tumours."

The team sequenced the full genomes of six chondroblastoma tumours and found that all six tumours had mutations in one of two related genes, H3F3A and H3F3B, which produce an identical protein, called histone 3.3.

Extending the study to more chondroblastoma tumours and to other bone tumours, they were able to verify that this mutation was found in almost all cases of chondroblastoma. Interestingly, the team also observed that most cases of a different type of bone tumour, giant cell tumour of bone, have a mutation in the H3F3A gene, albeit in a different position in the gene. A pattern emerged where both tumour types, chondroblastoma and giant cell tumour of bone, are defined by specific histone 3.3 mutations.

The team pinpointed the specificity of these mutations to affecting a single amino acid residue on the histone 3.3 protein; G34W amino acid residue underlies giant cell tumour of the bone and K36M amino acid residue underlies chondroblastoma.

"The high prevalence of these mutations in each tumour type is striking, but what's most remarkable is the unprecedented specificity of these mutations," says Dr Sam Behjati, first author from the Wellcome trust Sanger Institute. "The specificity of the mutations not only informs us about how these tumours develop, but also points to some fundamental function of these genes in normal bone development."

"Our findings will be highly beneficial to clinicians as we now have a diagnostic marker to differentiate chondroblastoma and giant cell tumour of bones from other bone tumours," says Professor Adrienne Flanagan, co-lead author from the Royal National Orthopaedic Hospital, and UCL Cancer Institute. "This study highlights the importance of continuing to sequence all types of human cancer."

"We are also extremely grateful to our patients and collaborators, without their help we would not have been able to study these extremely rare diseases," adds Professor Flanagan.


'/>"/>

Contact: Aileen Sheehy
press.office@sanger.ac.uk
0044-012-234-92368
Wellcome Trust Sanger Institute
Source:Eurekalert

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
Breaking Biology News(10 mins):
(Date:5/20/2016)... ... May 20, 2016 , ... The recent recall by Costco and Trader Joes ... News on May 12, 2016(1), demonstrates the need for faster and more cost effective ... firm, PathSensors, Inc. , PathSensor’s latest solution uses a biosensor technology ...
(Date:5/19/2016)... 2016 There is no saying ... the relentless pressures in pricing and lack in consumer ... circle though - numerous opportunities are up for grabs ... ActiveWallSt.com,s presents four names in this sector: Portola Pharmaceuticals ... (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... MADRID , May 19, 2016 ... di una sessione orale durante il 52 ° ... (abstract n. 8006)    - Le conclusioni ... quanto riguarda i pazienti trattati, di cui il 90% presenta ... di sei mesi o più. Il settantadue per cento dei ...
(Date:5/18/2016)... May 18, 2016 The Biotech industry ... not mean that there are no opportunities ahead. Today, ActiveWallSt.com ... (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... and Ophthotech Corp. (NASDAQ: OPHT ). Sign up ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s ...
Breaking Biology Technology: